MEDA Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Stage IV Natural Killer/T-cell Lymphoma

NACompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

February 29, 2020

Study Completion Date

February 29, 2020

Conditions
Extranodal NK-T-Cell Lymphoma, Nasal Type
Interventions
DRUG

MEDA

"Methotrexate, 3.0g/m2/d iv, day 1~Etoposide, 100mg/m2 iv, day 2 to day 4~Dexamethasone, 40mg/d iv, day 1 to day 4~Pegaspargase, 2500IU/m2/d im, day 4~The MEDA chemotherapy will be repeated every 3 weeks."

PROCEDURE

Auto-HSCT

Auto-HSCT will be performed with patients who responded to the initial MEDA chemotherapy with standard BEAM conditioning regimen.

Trial Locations (7)

200011

Shanghai Ninth People's Hospital, Shanghai

200031

Shanghai Eye Ear Nose and Throat Hospital, Fudan University, Shanghai

200032

Zhongshan Hospital, Fudan University, Shanghai

200092

Xinhua Hospital, Shanghai

200120

Shanghai Dong Fang hospital, Shanghai

200336

Shanghai Tong Ren Hospital, Shanghai

830001

Xin Jiang People's Hospital, Ürümqi

All Listed Sponsors
lead

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

NCT02764281 - MEDA Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Stage IV Natural Killer/T-cell Lymphoma | Biotech Hunter | Biotech Hunter